Brojatsch Jürgen, Lima Heriberto, Kar Alak K, Jacobson Lee S, Muehlbauer Stefan M, Chandran Kartik, Diaz-Griffero Felipe
Albert Einstein College of Medicine, Department of Microbiology and Immunology, Bronx, New York, United States of America.
PLoS One. 2014 Jun 3;9(6):e95032. doi: 10.1371/journal.pone.0095032. eCollection 2014.
Recent studies have linked necrotic cell death and proteolysis of inflammatory proteins to the adaptive immune response mediated by the lysosome-destabilizing adjuvants, alum and Leu-Leu-OMe (LLOMe). However, the mechanism by which lysosome-destabilizing agents trigger necrosis and proteolysis of inflammatory proteins is poorly understood. The proteasome is a cellular complex that has been shown to regulate both necrotic cell death and proteolysis of inflammatory proteins. We found that the peptide aldehyde proteasome inhibitors, MG115 and MG132, block lysosome rupture, degradation of inflammatory proteins and necrotic cell death mediated by the lysosome-destabilizing peptide LLOMe. However, non-aldehyde proteasome inhibitors failed to prevent LLOMe-induced cell death suggesting that aldehyde proteasome inhibitors triggered a pleotropic effect. We have previously shown that cathepsin C controls lysosome rupture, necrotic cell death and the adaptive immune response mediated by LLOMe. Using recombinant cathepsin C, we found that aldehyde proteasome inhibitors directly block cathepsin C, which presumably prevents LLOMe toxicity. The cathepsin B inhibitor CA-074-Me also blocks lysosome rupture and necrotic cell death mediated by a wide range of necrosis inducers, including LLOMe. Using cathepsin-deficient cells and recombinant cathepsins, we demonstrate that the cathepsins B and C are not required for the CA-074-Me block of necrotic cell death. Taken together, our findings demonstrate that lysosome-destabilizing adjuvants trigger an early proteolytic cascade, involving cathepsin C and a CA-074-Me-dependent protease. Identification of these early events leading to lysosome rupture will be crucial in our understanding of processes controlling necrotic cell death and immune responses mediated by lysosome-destabilizing adjuvants.
最近的研究已将坏死性细胞死亡以及炎症蛋白的蛋白水解与由溶酶体去稳定化佐剂明矾和亮氨酸-亮氨酸-甲酯(LLOMe)介导的适应性免疫反应联系起来。然而,溶酶体去稳定化剂触发炎症蛋白坏死和蛋白水解的机制仍知之甚少。蛋白酶体是一种细胞复合物,已被证明可调节坏死性细胞死亡和炎症蛋白的蛋白水解。我们发现肽醛蛋白酶体抑制剂MG115和MG132可阻断由溶酶体去稳定化肽LLOMe介导的溶酶体破裂、炎症蛋白降解和坏死性细胞死亡。然而,非醛蛋白酶体抑制剂未能预防LLOMe诱导的细胞死亡,这表明醛蛋白酶体抑制剂引发了多效性效应。我们之前已表明组织蛋白酶C控制溶酶体破裂、坏死性细胞死亡以及由LLOMe介导的适应性免疫反应。使用重组组织蛋白酶C,我们发现醛蛋白酶体抑制剂直接阻断组织蛋白酶C,这大概可防止LLOMe毒性。组织蛋白酶B抑制剂CA-074-Me也可阻断由包括LLOMe在内的多种坏死诱导剂介导的溶酶体破裂和坏死性细胞死亡。使用组织蛋白酶缺陷细胞和重组组织蛋白酶,我们证明组织蛋白酶B和C并非CA-074-Me阻断坏死性细胞死亡所必需。综上所述,我们的研究结果表明,溶酶体去稳定化佐剂触发了一个早期蛋白水解级联反应,涉及组织蛋白酶C和一种CA-074-Me依赖性蛋白酶。识别这些导致溶酶体破裂的早期事件对于我们理解控制由溶酶体去稳定化佐剂介导的坏死性细胞死亡和免疫反应的过程至关重要。